Wei, M., Elias, A. D., Giridhar, K., Goetz, M. P., Mukhtar, R., Vaklavas, C., Veer, L. V. T., Alkhafaji, S., Hirst, G. L., Rugo, H. S., Chen, N., Symmans, W. F. F., Borowsky, A. D., Swigart, L. B., Onishi, N., Yee, D., Hylton, N., Esserman, L., Chien, J. (2025). I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.612